Form 4: Dexcom Executive Matthew Dolan Sells Shares Under 10b5-1 Plan
SEC Form 4
Matthew Dolan, EVP of Strategy and Corporate Development at Dexcom Inc., sold 1,990 shares of common stock at $137.81 per share on April 15, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 15, 2024, Matthew Dolan, the EVP of Strategy and Corporate Development at Dexcom Inc., sold 1,990 shares of Dexcom's common stock.
- The sale was executed at a price of $137.81 per share.
- This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted by Mr. Dolan on December 15, 2023.
- Following the transaction, Mr. Dolan beneficially owns 42,377 shares of Dexcom common stock.
- This total includes 40,075 unvested restricted stock units (RSUs) that vest through March 8, 2027.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an executive's stock sale under a pre-arranged plan, indicating a neutral sentiment.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies and are often conducted under pre-arranged trading plans like 10b5-1 plans to avoid accusations of insider trading. These plans allow insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 12/15/2023 | Mr. Dolan adopted a 10b5-1 Plan. |
| 03/08/2022 | Grant date for 3,852 restricted stock units vesting through March 8, 2025. |
| 03/08/2023 | Grant date for 14,512 restricted stock units vesting through March 8, 2026. |
| 03/08/2024 | Grant date for 21,711 restricted stock units vesting through March 8, 2027. |
| 04/15/2024 | Date of stock sale transaction. |
| 04/16/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.